Lung最新文献

{"title":"MUC5B/TGF-β/KL-6 Signaling in Idiopathic Pulmonary Fibrosis: Genetic Susceptibility to Profibrotic Progression and Clinical Perspectives.","authors":"Sreedhara Muppana Venkatesharao, Anbu Jayaraman","doi":"10.1007/s00408-026-00954-3","DOIUrl":"https://doi.org/10.1007/s00408-026-00954-3","url":null,"abstract":"<p><p>Idiopathic pulmonary fibrosis (IPF) is a progressive fibrotic lung disorder strongly mediated by genetic susceptibility and aberrant epithelial repair mechanisms. Among the identified genetic factors, the MUC5B promoter polymorphism rs35705950 represents the most significant and frequently replicated risk variant associated with both familial and sporadic IPF. This review focuses on the mechanistic role of MUC5B dysregulation in promoting epithelial dysfunction and profibrotic signalling, with particular emphasis on its interaction with transforming growth factor-beta (TGF-β) signalling and KL-6-associated epithelial injury. Excessive MUC5B expression within distal airways disrupts mucociliary homeostasis, prolongs epithelial exposure to inhaled toxic stimuli, and enhances persistent alveolar stress, thereby facilitating chronic epithelial injury and aberrant tissue repair. Sustained epithelial damage subsequently activates TGF-β-mediated SMAD signalling pathways, promoting fibroblast activation, myofibroblast differentiation, and extracellular matrix deposition. Emerging evidence further suggests a close relationship between MUC5B-associated epithelial dysfunction and elevated KL-6 expression, indicating that KL-6 may function as a downstream biomarker indicating ongoing epithelial injury and fibrotic progression. The proposed MUC5B/TGF-β/KL-6 mechanistic signaling provides an integrated molecular network linking genetic susceptibility, epithelial dysfunction, biomarker elevation, and progressive fibrosis in IPF. In addition, telomere-related and surfactant-associated gene mutations further lead to epithelial instability and impaired regenerative capacity. Together, these interconnected molecular mechanisms provide significant insights into IPF progression and may support the development of biomarker-driven prognostic approaches and targeted precision therapies for improved disease management.</p>","PeriodicalId":18163,"journal":{"name":"Lung","volume":"204 1","pages":""},"PeriodicalIF":4.3,"publicationDate":"2026-10-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149228136","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Indirect Echocardiographic Signs of Increased Right-sided Afterload in Progressive Pulmonary Fibrosis: Insights from a Multicentre Italian Study.","authors":"Jacopo Cefalo, Andrea Baccelli, Francesco Varone, Fabrizio Luppi, Paolo Cameli, Stefania Cerri, Alberto Gerli, Mattia Nastasi, Bruno Iovene, Alessia Martini, Giovanni Franco, Umberto Zanini, Tommaso Pianigiani, Athina Patsoura, Luca Richeldi, Elena Bargagli, Giovanni Sotgiu, Michele Mondoni","doi":"10.1007/s00408-026-00955-2","DOIUrl":"https://doi.org/10.1007/s00408-026-00955-2","url":null,"abstract":"<p><strong>Purpose: </strong>Pulmonary vascular involvement is a determinant of worse outcomes in fibrotic lung diseases. Its prevalence and prognostic relevance in patients with progressive pulmonary fibrosis (PPF) is unknown. The aim of this study was to assess the prevalence of indirect echocardiographic abnormalities in progressive pulmonary fibrosis before antifibrotic therapy, characterize a baseline high-risk cardiopulmonary functional profile, and assess 12-month clinical trajectories.</p><p><strong>Methods: </strong>Observational, retrospective, multicentre study.</p><p><strong>Results: </strong>158 patients (median (IQR) age of 71 (65.2-77.0) years) with PPF were enrolled. Thirty (19.0%) had ≥ 1 echocardiographic indirect sign of increased right-sided afterload, 15 (9.5%) ≥ 2, 9 (5.7%) ≥ 3 and 1 (0.6%) all four. A shortened right ventricular outflow tract acceleration time (< 105 ms) was the most frequent alteration (12.7%), followed by right atrial dilation (10.8%). In univariable analysis, ≥1 sign was associated with male sex, a lower DLCO% predicted, a higher FVC%/DLCO% ratio and a shorter 6MWD; in the multivariable model only, male sex remained independently associated (aOR 3.45, 95% CI 0.99-12.07; p = 0.052). Twelve-month FVC trajectories did not differ by baseline echocardiographic status; nonetheless, ≥1 sign was associated with shorter time to acute exacerbation (log-rank p = 0.007) and all-cause hospitalisation (p = 0.001).</p><p><strong>Conclusions: </strong>Echocardiographic signs suggestive of increased right-sided afterload are present in a substantial proportion of PPF patients at the time of antifibrotic initiation. They identified patients at higher risk of acute exacerbation and hospitalisation, regardless of FVC decline. This higher-risk subgroup warrants specific pulmonary vascular evaluation and tighter clinical follow-up.</p>","PeriodicalId":18163,"journal":{"name":"Lung","volume":"204 1","pages":""},"PeriodicalIF":4.3,"publicationDate":"2026-10-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149220426","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Sample Adequacy PD-L1 and NGS in NSCLC: Shape-Sensing Robotic Assisted Bronchoscopy Versus CT Guided Lung Biopsy.","authors":"Sebastian Fernandez-Bussy, Tatiana A Rojas-Zapata, Alejandra Yu Lee-Mateus, Regina Murillo-Torres, Lorna Evans, Andras Khoor, Ryan M Chadha, Linh H Vu, Bryan C Husta, David Abia-Trujillo","doi":"10.1007/s00408-026-00949-0","DOIUrl":"https://doi.org/10.1007/s00408-026-00949-0","url":null,"abstract":"<p><strong>Background: </strong>Routine assessment of programmed death-ligand 1 (PD-L1) expression and comprehensive next-generation sequencing (NGS) is recommended to guide treatment selection in patients with non-small cell lung cancer (NSCLC). Obtaining adequate tissue for biomarker and molecular analyses is therefore essential. This study compared sample adequacy for PD-L1 and NGS testing between shape-sensing robotic-assisted bronchoscopy (ssRAB) and computed tomography-guided transthoracic lung biopsy (CTTB) in patients with NSCLC.</p><p><strong>Methods: </strong>We conducted a single-center retrospective study of patients with NSCLC who underwent biopsy of PPL by ssRAB or CTTB between June 2020 and December 2025. Demographic, procedural, pathological, biomarker and molecular data were extracted from electronic medical records, and descriptive statistics analysis and multivariable logistic regression were performed.</p><p><strong>Results: </strong>A total of 402 patients were included, comprising 198 in the ssRAB cohort and 204 in the CTTB cohort. ssRAB demonstrated significantly higher sample adequacy rates than CTTB for both PD-L1 (98.8% vs. 90.6%, p < 0.001) and NGS testing (92.3% vs. 79.1%, p = 0.005). In multivariable logistic regression analyses, ssRAB was independently associated with higher odds of PD-L1 sample adequacy (adjusted OR 11.48, 95% CI 2.89-78.30; p = 0.002) and NGS sample adequacy (adjusted OR 4.01, 95% CI 1.64-11.40; p = 0.004) compared with CTTB. In a separate model evaluating biopsy tools, cryobiopsy use was independently associated with higher odds of PD-L1 adequacy (adjusted OR 16.54, 95% CI 2.92-317.65; p = 0.010) and NGS adequacy (adjusted OR 5.83, 95% CI 1.93-25.39; p = 0.006) compared with non-cryobiopsy sampling.</p><p><strong>Conclusions: </strong>ssRAB-acquired specimens were associated with higher rates of PD-L1 and NGS sample adequacy than CTTB-acquired specimens in patients with NSCLC. Future prospective studies are needed to better understand the procedural and specimen-related factors underlying these differences.</p>","PeriodicalId":18163,"journal":{"name":"Lung","volume":"204 1","pages":""},"PeriodicalIF":4.3,"publicationDate":"2026-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149182901","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Phenotype-Guided Surfactant Therapy in ARDS: From Failed Replacement to Targeted Biological Intervention, Narrative Review.","authors":"Petra Hornakova Kosutova, Maria Belancova, Pavol Mikolka","doi":"10.1007/s00408-026-00947-2","DOIUrl":"10.1007/s00408-026-00947-2","url":null,"abstract":"<p><strong>Purpose of review: </strong>Acute respiratory distress syndrome (ARDS) is associated with profound pulmonary surfactant dysfunction, yet clinical trials of exogenous surfactant have not demonstrated consistent outcome benefits in adults. This review reassesses these failures in light of current understanding of ARDS heterogeneity, surfactant biology and intrapulmonary drug delivery.</p><p><strong>Recent findings: </strong>Surfactant dysfunction in ARDS reflects not only quantitative depletion but also inhibition by plasma proteins, altered lipid and protein composition, impaired synthesis and recycling, epithelial injury and heterogeneous alveolar flooding. Previous trials frequently enrolled biologically unselected populations and used variable formulations, doses and delivery strategies. Available evidence provides a rationale for a phenotype-guided approach integrating patient selection, assessment of surfactant dysfunction, formulations capable of maintaining activity under inhibitory conditions and optimized alveolar delivery. Next-generation synthetic surfactants containing surfactant protein B and C analogues, together with surfactant-based delivery of anti-inflammatory or other biologically active compounds, may address limitations of earlier replacement strategies. Future studies should move beyond testing surfactant in unselected ARDS. Clinical translation will require biologically enriched populations, mechanistically appropriate formulations, early treatment and verified delivery to recruitable lung regions.</p>","PeriodicalId":18163,"journal":{"name":"Lung","volume":"204 1","pages":""},"PeriodicalIF":4.3,"publicationDate":"2026-10-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149111722","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Contemporary Chemotherapy Benchmarks for Molecularly Defined Advanced NSCLC: Reconstructed Individual Patient-Level Data of 22 Randomized Trials.","authors":"Deborah Di-Xin Zhou, Sarah J Lord, Frank Lin, Thomas John, Robert John Simes, Chee Khoon Lee","doi":"10.1007/s00408-026-00946-3","DOIUrl":"10.1007/s00408-026-00946-3","url":null,"abstract":"<p><strong>Purpose: </strong>The increasing adoption of targeted therapies over chemotherapy has made randomized controlled trials (RCT) with chemotherapy increasingly challenging in advanced NSCLC with actionable genomic alterations (AGA), particularly for rare subgroups. Contemporary chemotherapy outcomes specific to AGAs are lacking despite growing reliance on single-arm studies and external-control analyses. We sought to establish first-line platinum-doublet chemotherapy outcomes in advanced NSCLC with AGAs using data from RCTs.</p><p><strong>Methods: </strong>We extracted objective response rate (ORR), progression-free survival (PFS), and overall survival (OS) data from Phase 2/3 RCTs. Individual patient-level data were reconstructed from Kaplan-Meier curves to pool and compare PFS and OS across AGAs.</p><p><strong>Results: </strong>Twenty-two RCTs (n = 2132) were included. Across most AGAs, platinum-doublet chemotherapy produced similar outcomes-pooled ORRs ranging from 28.7 to 39.0% and median PFS from 6.0 to 7.3 months. Pairwise comparisons showed better ORR/PFS for RET fusion (one trial with control arm-chemotherapy/pembrolizumab) and shorter OS for KRAS mutation versus other AGAs (logrank P<.001). Detailed pooled ORR and median PFS and OS were: ALK rearrangement (n = 461)-ORR 39.0% (95% CI 25.8-52.2), PFS 7.0 months (6.8-7.2), OS 43.0 months (32.2-inestimable); common EGFR mutation (n = 1038)-ORR 28.7% (22.3-35.1), PFS 6.0 months (5.7-6.3), OS 27.4 months (26.1-29.3); uncommon EGFR mutation (n = 61)-ORR 35.1% (12.6-57.7), PFS 6.7 months (5.2-8.4), OS 29.5 months (13.3-inestimable); EGFR exon 20 insertion (n = 330)-ORR 38.3% (21.7-55.0), PFS 7.3 months (6.9-8.6), OS 30.1 months (29.1-inestimable); KRAS mutation (n = 140)-ORR 21.7% (12.4-30.9), PFS 6.2 months (4.7-6.9), OS 10.8 months (8.8-12.7); RET fusion (n = 102)-ORR 65.0% (54.5-75.5), PFS 11.4 months (8.9-16.9), OS not available.</p><p><strong>Conclusion: </strong>Platinum-doublet chemotherapy yields remarkably consistent ORR and PFS across most advanced NSCLC with AGAs. These data provide contemporary molecularly defined benchmarks that may support interpretation of single-arm studies, development of external-control analyses, and future trial design in this rare population.</p>","PeriodicalId":18163,"journal":{"name":"Lung","volume":"204 1","pages":""},"PeriodicalIF":4.3,"publicationDate":"2026-10-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13645942/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149128018","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Therapeutic Treatment with a Clinically Relevant Dose of Dexamethasone Reduces Pulmonary Vascular Leak in a Mouse Model of ARDS.","authors":"Hannah C Little-Hooy, Sreehari Kalvakuri, Donghong Yan, Ran Li, Jing Kang, Alicia Vargas, Hua Zhang, Sharookh B Kapadia, Subba Chintalacharuvu, Min Xu","doi":"10.1007/s00408-026-00945-4","DOIUrl":"10.1007/s00408-026-00945-4","url":null,"abstract":"<p><strong>Purpose: </strong>Acute Respiratory Distress Syndrome (ARDS) is a life-threatening acute lung injury with great unmet medical needs. Lung edema resulting from increased vascular leak is a hallmark of the disease. Recently corticosteroids were recommended for ARDS patients by the American Thoracic Society. Here, we use the influenza infection mouse model to study vascular leak induced by viral lung injury and the effect of dexamethasone on vascular leak and mortality.</p><p><strong>Methods: </strong>Near-infrared fluorescence (NIRF) imaging was used to quantitatively measure vascular leak in mice infected with influenza PR8, and the effect of dexamethasone was analyzed as a function of dose and time of the treatment.</p><p><strong>Results: </strong>NIRF imaging robustly detects vascular leak up to 14 days post-infection. Dexamethasone treatment reduces mortality and vascular leak when administered on day 9 post infection, corresponding to the time of influenza virus clearance. Early treatment of dexamethasone, either prophylactically or on day 5 post infection, has a negative impact on the host anti-viral response resulting in increase in viral titers and pro-inflammatory cytokines. Although the higher dexamethasone dose at 10 mg/kg shows a more potent pharmacodynamics effect in mice, 0.5 mg/kg dexamethasone is sufficient to reduce vascular leak.</p><p><strong>Conclusions: </strong>This study provides a clear link between timing of dexamethasone treatment and viral burden, vascular leak, and mortality. 0.5 mg/kg dexamethasone affects clinically relevant parameters in the influenza model and has comparable exposure to human dexamethasone dosing; thus it is a more relevant dose to use in future mouse studies.</p>","PeriodicalId":18163,"journal":{"name":"Lung","volume":"204 1","pages":""},"PeriodicalIF":4.3,"publicationDate":"2026-10-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149111742","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"\"Authors' Response: Social Vulnerability and Pulmonary Nodule Malignancy: Race, Mediation, and a Nodule-Level Mismatch Deserve Closer Scrutiny\".","authors":"Hafizaqib Ilyas, Talha Bin Kashif, Nicole M Geissen","doi":"10.1007/s00408-026-00942-7","DOIUrl":"https://doi.org/10.1007/s00408-026-00942-7","url":null,"abstract":"","PeriodicalId":18163,"journal":{"name":"Lung","volume":"204 1","pages":""},"PeriodicalIF":4.3,"publicationDate":"2026-10-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149111806","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical Characteristics and Outcomes of Patients with Lymphangioleiomyomatosis.","authors":"Hee-Young Yoon, Sung Woo Park, Jong Sun Park, Byoung Soo Kwon, Yong Suk Jo, Yangjin Jegal, Ju Hyun Oh, Joo Hun Park, Jae Ha Lee, Hongseok Yoo, Bo-Guen Kim, Tae Hun Kim, Jin Kyung Park, Ala Woo, Jin Woo Song","doi":"10.1007/s00408-026-00944-5","DOIUrl":"10.1007/s00408-026-00944-5","url":null,"abstract":"<p><strong>Background: </strong>Lymphangioleiomyomatosis (LAM) is a rare, progressive cystic lung disease that affects women of reproductive age. Although registries from Western countries have provided key insights, comprehensive nationwide data from Asian countries are scarce. This study aimed to characterise the clinical, functional and outcome features of Korean patients with LAM from a nationwide multicentre registry.</p><p><strong>Methods: </strong>We analyzed data from patients with LAM enrolled in the Korean Nationwide Rare Interstitial Lung Disease Registry in 2024. Data on clinical and functional characteristics were collected from 20 centers. Longitudinal changes in pulmonary function were assessed using linear mixed-effects models. Individual annual forced expiratory volume in 1 s (FEV₁) change rates were estimated using linear regression and analyzed to identify associated factors.</p><p><strong>Results: </strong>Eighty-six women (mean age, 47.3 years) were included; 50% were asymptomatic at diagnosis and 61.6% had complications, including pneumothorax (29.1%) and renal angiomyolipoma (25.6%). Baseline mean forced vital capacity (FVC) and FEV₁ were relatively preserved (89.6% and 78.7% predicted, respectively), whereas diffusing capacity for carbon monoxide was mildly reduced (64.3% predicted). Longitudinal analysis revealed no significant overall decline in lung function. However, cough at presentation and higher baseline FEV₁ or FVC were independently associated with disease progression. A total of 54.7% of patients received mechanistic target of rapamycin (mTOR) inhibitors, but no statistically significant differences in the rate of functional decline were observed between users and non-users.</p><p><strong>Conclusion: </strong>This study provides a nationwide characterization of LAM in Korea, showing preserved lung function at diagnosis and frequent mTOR inhibitor use.</p>","PeriodicalId":18163,"journal":{"name":"Lung","volume":"204 1","pages":""},"PeriodicalIF":4.3,"publicationDate":"2026-10-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149111725","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"NOP2 Exacerbates Pulmonary Inflammation in a Murine Model of Chronic Obstructive Pulmonary Disease by Inducing Neutrophil Extracellular Traps Mediating M1 Macrophage Polarization.","authors":"Chunyan Guo, Sai Chen, Zhuxiang Shao, Shengping Zhai","doi":"10.1007/s00408-026-00943-6","DOIUrl":"https://doi.org/10.1007/s00408-026-00943-6","url":null,"abstract":"<p><strong>Background: </strong>This study aims to explore the molecular mechanism of NOP2 in inducing neutrophil extracellular traps (NETs) and M1 macrophage polarization in a murine model of COPD.</p><p><strong>Methods: </strong>A murine model of COPD was established using cigarette smoke exposure combined with LPS stimulation. Lung pathological changes and fibrosis were evaluated by H&E and Masson staining. The inflammatory cytokines in bronchoalveolar lavage fluid and NETs-related biomarkers in serum were detected by ELISA. Immunofluorescence was applied to observe the colocalization of Cit-H3 with CD86/CD206 in lung tissues. In vitro, RAW264.7 macrophages were treated with cigarette smoke extract. NETs were induced by PMA and co-cultured with RAW264.7 cells. Cell viability, macrophage polarization, and the expression of NOP2, TUG1, TRIM27, EZH2, iNOS and Arg-1 were determined by CCK-8, flow cytometry, qRT-PCR or Western blot. MeRIP, actinomycin D assay, RNA pull-down, RIP and Co-IP were performed to detect m5C modification, TUG1 stability, molecular binding and EZH2 ubiquitination.</p><p><strong>Results: </strong>NOP2, TUG1 and TRIM27 were highly expressed in our murine model of COPD. NOP2 inhibition alleviated lung injury, suppressed NETs, M1 polarization and pulmonary inflammation. Mechanistically, NOP2 stabilized and elevated TUG1 expression via m5C modification. TUG1 acted as a molecular scaffold to recruit TRIM27 and EZH2, facilitating TRIM27-mediated EZH2 ubiquitination. TUG1 overexpression or EZH2 inhibition partially reversed the protective effects of NOP2 silencing.</p><p><strong>Conclusions: </strong>NOP2 aggravates pulmonary inflammation in a murine model of COPD by promoting NETs and M1 polarization via the TUG1/TRIM27/EZH2 axis.</p>","PeriodicalId":18163,"journal":{"name":"Lung","volume":"204 1","pages":""},"PeriodicalIF":4.3,"publicationDate":"2026-10-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149111739","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Social Vulnerability and Pulmonary Nodule Malignancy: Race, Mediation, and a Nodule-Level Mismatch Deserve Closer Scrutiny.","authors":"Fajar Farid, Haider Imran, Abdul Basit Munir","doi":"10.1007/s00408-026-00941-8","DOIUrl":"10.1007/s00408-026-00941-8","url":null,"abstract":"","PeriodicalId":18163,"journal":{"name":"Lung","volume":"204 1","pages":""},"PeriodicalIF":4.3,"publicationDate":"2026-10-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149111732","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}